Bibliography
- Farokhzad OC, Langer R. Nanomedicine: developing smarter therapeutic and diagnostic modalities. Adv Drug Deliv Rev 2006;58:1456-9
- Zhang L, Gu FX, Chan JM, Nanoparticles in medicine: therapeutic applications and developments. Clin Pharm Ther 2008;83:761-9
- Veronese FM, Pasut G. PEGylation, successful approach to drug delivery. Drug Discov Today 2005;10:1451-8
- Harris JM, Chess RB. Effect of pegylation on pharmaceuticals. Nat Rev Drug Discov 2003;2:214-21
- Knop K, Hoogenboom R, Fischer D, Schubert US. Poly(ethylene glycol) in drug delivery: pros and cons as well as potential alternatives. Angew Chem Int Ed 2010;49:6288-308
- Muzykantov VR. Drug delivery by red blood cells: vascular carriers designed by mother nature. Expert Opin Drug Deliv 2010;7:403-27
- Doshi N, Zahr AS, Bhaskar S, Red blood cell-mimicking synthetic biomaterial particles. Proc Natl Acad Sci USA 2009;106:21495-9
- Merkel TJ, Jones SW, Herlihy KP, Using mechanobiological mimicry of red blood cells to extend circulation times of hydrogel microparticles. Proc Natl Acad Sci USA 2011;108:586-91
- Oldenborg PA, Zheleznyak A, Fang YF, Role of CD47 as a marker of self on red blood cells. Science 2000;288:2051-4
- Schonermark S, Rauterberg EW, Shin ML, Homologous species restriction in lysis of human-erythrocytes – a membrane-derived protein with C8-binding capacity functions as an inhibitor. J Immun 1986;136:1772-6
- Zalman LS, Wood LM, Mullereberhard HJ. Isolation of a human-erythrocyte membrane-protein capable of inhibiting expression of homologous complement transmembrane channels. Proc Natl Acad Sci USA 1986;83:6975-9
- Kim DD, Miwa T, Kimura Y, Deficiency of decay-accelerating factor and complement receptor 1-related gene/protein y on murine platelets leads to complement-dependent clearance by the macrophage phagocytic receptor CRIg. Blood 2008;112:1109-19
- Tsai RK, Rodriguez PL, Discher DE. Self inhibition of phagocytosis: the affinity of 'marker of self' CD47 for SIRPalpha dictates potency of inhibition but only at low expression levels. Blood Cells Mol Dis 2010;45:67-74
- Desilets J, Lejeune A, Mercer J, Gicquaud C. Nanoerythrosomes, a new derivative of erythrocyte ghost: IV. Fate of reinjected nanoerythrosomes. Anticancer Res 2001;21:1741-7
- Hu CMJ, Zhang L, Aryal S, Erythrocyte membrane-camouflaged polymeric nanoparticles as a biomimetic delivery platform. Proc Natl Acad Sci USA 2011;108:10980-5